# China NMPA Product Recall - Infant phototherapy incubator, neonatal blue light therapy device

Source: https://www.globalkeysolutions.net/records/china_product_recall/likang-huayao-biotechnology-shanghai-co-ltd/8f10ed35-bed7-4487-abf4-c8b1564e289b/
Source feed: China

> China NMPA product recall for Infant phototherapy incubator, neonatal blue light therapy device by Likang Huayao Biotechnology (Shanghai) Co., Ltd. published November 13, 2017. Recall level: Level 3. The National Medical Products Administration (NMPA) announced a significant product recall initiated

---

## Details

- Record Type: CHINA_PRODUCT_RECALL
- Title: Likang Huayao Biotechnology (Shanghai) Co., Ltd. has voluntarily recalled its infant phototherapy incubators and neonatal blue light therapy devices.
- Company Name: Likang Huayao Biotechnology (Shanghai) Co., Ltd.
- Publication Date: 2017-11-13
- Product Name: Infant phototherapy incubator, neonatal blue light therapy device
- Recall Level: Level 3
- Recall Reason: The product's factory inspection report contains missing or incomplete testing parameters.
- Discovering Company: Likang Huayao Biotechnology (Shanghai) Co., Ltd.
- Manufacturing Company: Likang Huayao Biotechnology (Shanghai) Co., Ltd.
- Summary: The National Medical Products Administration (NMPA) announced a significant product recall initiated by Likang Huayao Biotechnology (Shanghai) Co., Ltd. On November 13, 2017, the company commenced a voluntary Class III recall affecting its infant phototherapy warmers (NMPA Approval No. 20143540987) and neonatal blue light therapy devices (Shanghai Medical Device Registration Certificate No. 20142260253). The critical issue identified was that factory inspection reports for these medical products contained incomplete or missing crucial test parameters. This deficiency in documentation raised concerns regarding product quality assurance and adherence to established manufacturing and testing protocols. Operating under the NMPA's regulatory framework, the company's proactive recall action is a direct response to these findings. The recall requires the immediate removal of all specified models, specifications, and batches from distribution, with comprehensive details provided in the 'Medical Device Recall List.' This event highlights the stringent oversight by the NMPA to ensure the safety and efficacy of medical devices, emphasizing the necessity for manufacturers to uphold meticulous record-keeping and robust quality control processes throughout a product's lifecycle, from manufacturing to market.

Company: https://www.globalkeysolutions.net/companies/likang-huayao-biotechnology-shanghai-co-ltd/a9367c94-dcc5-49c7-b7fe-02c2c05c8569/